The girl’s illness was unusually severe. Laboratory testing showed she carried two distinct disease-driving antibodies at once: myeloperoxidase-ANCA and proteinase 3-ANCA, a dual positivity found in only about 13 percent of pediatric cases. Her kidneys were under attack, with heavy proteinuria peaking at a spot urinary protein-to-creatinine ratio of 2,018.6 mg/g, a level indicating significant glomerular injury. Most alarming was the lung hemorrhage, which in vasculitis signals active inflammation of the pulmonary capillaries. Simply stopping the offending drug, the standard first move in drug-induced autoimmunity, proved insufficient. Her disease remained clinically active, forcing her medical team to escalate to pulsed intravenous methylprednisolone, a high-dose corticosteroid regimen designed to rapidly suppress the immune storm, followed by seven cycles of cyclophosphamide, a potent chemotherapy agent repurposed as an immunosuppressant, at a cumulative dose of 164.7 mg per kilogram of body weight.

What makes the case scientifically interesting is what happened next. Even after the drug was withdrawn and aggressive immunosuppression delivered, the autoimmune process did not switch off on its own schedule. The authors argue this pattern is consistent with autonomous autoimmunity, meaning the immune response, once triggered, sustains itself independently of the original chemical trigger. The observation carries a practical warning for clinicians: pediatric antithyroid drug-induced vasculitis cannot always be managed by drug withdrawal alone, and severe presentations such as diffuse alveolar hemorrhage demand the same aggressive immunosuppressive protocols used for primary, non-drug-induced forms of the disease. The authors are careful to note that this inference rests on limited observational evidence rather than controlled trials, a caveat that applies to nearly everything known about this rare condition.

To place their patient in context, the team systematically searched PubMed through September 2026 and the Chinese databases CNKI and Wanfang, identifying 37 published studies describing 53 pediatric cases of antithyroid drug-induced ANCA-associated vasculitis in patients aged 18 or younger. Adding their index case brought the combined dataset to 54 children treated between 1994 and 2026. The demographic profile is striking: 85.2 percent were female and the mean age was 13.0 years, with a range of 7 to 18. This female predominance mirrors the epidemiology of Graves’ disease itself, which disproportionately affects adolescent girls, since only children receiving antithyroid drugs are at risk of the complication. The long time span reflects growing recognition of the syndrome since the first reports appeared three decades ago.

The organ-by-organ breakdown of the 54 cases reveals a disease that behaves much like its adult counterpart. Renal involvement was the most common manifestation, affecting 74.1 percent of children, typically as a pauci-immune glomerulonephritis in which inflammatory damage to the kidney’s filtering units causes blood and protein to leak into the urine. Cutaneous involvement, often as palpable purpura or ulcerating skin lesions, affected 42.6 percent, while pulmonary disease, ranging from cough and hemoptysis to life-threatening alveolar hemorrhage, affected 37.0 percent. The triad of kidney, skin and lung involvement reflects the underlying pathology: ANCA-activated neutrophils attacking small vessels wherever they cluster, and the kidneys, with their dense capillary networks, bearing the heaviest burden.

Outcomes across the dataset were mixed but mostly favorable. Complete remission was achieved in 32 of the 54 children, or 59.3 percent, while 18, or 33.3 percent, achieved partial remission, a group that included one patient who progressed to end-stage renal disease, the permanent loss of kidney function requiring dialysis or transplantation. Three children died, a mortality of 5.6 percent, and one was lost to follow-up. These figures underscore that although drug-induced vasculitis is often assumed to be milder than the primary autoimmune form, in children it can be lethal or organ-threatening, particularly when the lungs or kidneys are involved. The review also highlights a striking gap in management: definitive treatment of the underlying Graves’ disease with radioactive iodine-131 during active vasculitis was reported in only two pediatric cases, one of which is the present index patient.

The use of iodine-131 in this girl’s case deserves particular attention. Antithyroid drugs work by blocking hormone synthesis, but in patients who develop vasculitis they become the enemy, leaving clinicians with a dilemma: the hyperthyroidism still needs definitive treatment, yet the standard medications are now contraindicated. Radioactive iodine offers an alternative, destroying the overactive thyroid tissue through targeted beta radiation, but administering it while the immune system is in open revolt against blood vessels is a decision few teams have made. The successful use of iodine-131 ablation in this patient, alongside her immunosuppressive therapy, suggests it may be a feasible definitive option in selected children, though with only two published pediatric precedents the evidence base remains thin and the authors frame it as a consideration for specific cases rather than a general recommendation.

Perhaps the most conceptually intriguing finding is what the follow-up revealed about antibodies. At 18 months, the girl’s clinical disease had resolved completely: the lung hemorrhage and proteinuria were gone. Yet her myeloperoxidase-ANCA remained persistently positive even as the proteinase 3-ANCA had normalized. This mismatch between laboratory markers and clinical state, termed serological-activity dissociation, is a recognized phenomenon in ANCA-associated vasculitis but is poorly characterized in children. It matters practically because physicians often use ANCA titers to gauge disease activity and guide treatment decisions. If antibodies can persist for years after the disease has burned out, treating the number rather than the patient risks unnecessary immunosuppression, with all its infectious and toxic costs, in a child who is actually in remission.

The broader significance of the report lies in its timing and its population. Propylthiouracil-induced vasculitis is well documented in adults, but pediatric data have been scattered across case reports for three decades without systematic synthesis. By pooling 54 cases, the study establishes benchmarks for frequency of organ involvement, dual antibody positivity, remission rates and mortality that clinicians can use when counseling families and weighing treatment choices. It also feeds into an ongoing debate about antithyroid drug safety in children: propylthiouracil carries a known risk of severe liver injury as well as vasculitis, while methimazole, the other first-line agent, has its own teratogenic profile, leaving pediatric endocrinologists to navigate a genuinely difficult risk landscape when treating adolescent Graves’ disease.

For now, the girl at the center of the report is doing well, her lungs clear and her kidneys recovered, her thyroid definitively ablated, her antibodies a lingering molecular echo of an illness her immune system has otherwise forgotten. Her case adds a data point to a rare disease and a caution to a common practice: the drugs that quiet an overactive thyroid can, in a small fraction of children, ignite an autoimmune fire that no longer needs them to keep burning. The authors’ synthesis of three decades of published cases gives pediatricians both a map of that fire and, in persistent antibody positivity, a reminder that the laboratory and the bedside do not always tell the same story.

Subject of Research: Propylthiouracil-induced ANCA-associated vasculitis in children with Graves' disease

Article Title: Pediatric antithyroid drug-induced ANCA-associated vasculitis: disease persistence, serological-activity dissociation, and the role of ¹³¹I therapy — a case report of propylthiouracil-induced diffuse alveolar hemorrhage and systematic review of 53 published pediatric cases

Article References: Wu, P., Chen, Z., & Xiao, Y. (2026). Pediatric antithyroid drug-induced ANCA-associated vasculitis: disease persistence, serological-activity dissociation, and the role of ¹³¹I therapy — a case report of propylthiouracil-induced diffuse alveolar hemorrhage and systematic review of 53 published pediatric cases. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07801-7

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07801-7

Keywords: propylthiouracil, ANCA-associated vasculitis, pediatrics, Graves' disease, diffuse alveolar hemorrhage, MPO-ANCA, PR3-ANCA, radioactive iodine-131, cyclophosphamide, systematic review, microscopic polyangiitis, serological-activity dissociation